Overall survival by RAS mutant status. (A) Overall survival (Kaplan-Meier) of patients treated within AML10 and AML12 clinical trials by NRAS mutation status. (B) Overall survival (Kaplan-Meier) of patients treated within AML10 and AML12 clinical trials by KRAS mutation status.